Clinical Trials Browser

Testicular Germ Cell Tumor, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Mesothelioma, Sarcoma, Stomach Neoplasms

NCT05789069 2025-11-21

A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

Phase 1 Active not recruiting

83 enrolled

DermatologicGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Stomach Neoplasms, Colorectal Neoplasms

NCT04363801 2025-10-09

DisTinGuish

Phase 2 Terminated

247 enrolled 38 charts

Gastrointestinal

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT05632939 2025-09-10

ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.

Phase 1/2 Active not recruiting

62 enrolled

Gastrointestinal

Stomach Neoplasms

NCT07098104 2025-08-01

A Benefit Population Atlas of nICT Versus nCT for LAGC

Completed

291 enrolled

Gastrointestinal

Stomach Neoplasms

NCT06793917 2025-07-20

Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Phase 3 Recruiting

269 enrolled

Gastrointestinal

Stomach Neoplasms

NCT06939439 2025-07-01

Using ctDNA to Guide Treatment Decisions for Stage III Gastric Cancer

Phase 3 Active not recruiting

416 enrolled

Gastrointestinal

Stomach Neoplasms

NCT04963088 2025-06-26

TALENT

Phase 1/2 Completed

65 enrolled

Gastrointestinal

Stomach Neoplasms

NCT06157996 2025-05-30

Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore

Phase 2 Recruiting

92 enrolled

Gastrointestinal

Stomach Neoplasms

NCT04579757 2025-05-08

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Phase 1/2 Terminated

87 enrolled 29 charts

EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

Clinical Trials

HERIZON-GEA-01

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

NeoTISLEGA

A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

DisTinGuish

ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.

A Benefit Population Atlas of nICT Versus nCT for LAGC

Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Using ctDNA to Guide Treatment Decisions for Stage III Gastric Cancer

TALENT

Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors